{"url_path":"/sec/mltx/8-k/2026-07-15/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/1821586/0001213900-26-078031-index.html","accession_number":"0001213900-26-078031","cik":"0001821586","ticker":"MLTX","issuer_name":"MoonLake Immunotherapeutics","edgar_url":"https://www.sec.gov/Archives/edgar/data/1821586/0001213900-26-078031-index.html","primary_entity_key":"0001821586","primary_entity_name":"MoonLake Immunotherapeutics"},"word_count":169,"has_tables":true,"body_markdown":"** **\n\n**Item\n8.01. Other Events.**\n\n \n\nOn\nJuly 10, 2026, the underwriters of the previously announced public offering of Class A ordinary shares, par value $0.0001 per share (the\n“Ordinary Shares”), of MoonLake Immunotherapeutics (the “Company”) and, in lieu of Ordinary Shares to certain\ninvestors that so choose, pre-funded warrants to purchase Ordinary Shares, exercised in full their option (the “Option”)\nto purchase an additional 1,500,000 Ordinary Shares (the “Option Shares”). As a result of the exercise of the Option, the\nCompany received additional gross proceeds of $30.0 million from the sale of the Option Shares, before deducting underwriting\ndiscounts and commissions and offering expenses. The closing of the issuance and sale of the Option Shares occurred on July 14, 2026.\n\n \n\n1\n\n \n\n** **\n\n**SIGNATURE**\n\n** **\n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**MOONLAKE\nIMMUNOTHERAPEUTICS**\n\n \n \n\nDate: July 14, 2026\nBy:\n/s/\nMatthias Bodenstedt                          \n\n \nName: \nMatthias\nBodenstedt\n\n \nTitle:\nChief\nFinancial Officer\n\n \n\n2"}